Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.creator | Terpos, E. (Evangelos) | - |
dc.creator | Kostopoulos, I.V. (Ioannis V.) | - |
dc.creator | Kastritis, E. (Efstathios) | - |
dc.creator | Ntanasis-Stathopoulos, I. (Ioannis) | - |
dc.creator | Migkou, M. (Magdalini) | - |
dc.creator | Rousakis, P. (Pantelis) | - |
dc.creator | Argyriou, A.T. (Alexandra T.) | - |
dc.creator | Kanellias, N. (Nikolaos) | - |
dc.creator | Fotiou, D. (Despina) | - |
dc.creator | Eleutherakis-Papaiakovou, E. (Evangelos) | - |
dc.creator | Gavriatopoulou, M. (Maria) | - |
dc.creator | Ziogas, D.C. (Dimitrios C.) | - |
dc.creator | Papanota, A.M. (Aristea-Maria) | - |
dc.creator | Spyropoulou-Vlachou, M. (Marilyn) | - |
dc.creator | Trougakos, I.P. (Ioannis P.) | - |
dc.creator | Tsitsilonis, O.E. (Ourania E.) | - |
dc.creator | Paiva, B. (Bruno) | - |
dc.creator | Dimopoulos, M.A. (Meletios A.) | - |
dc.date.accessioned | 2021-10-26T10:37:08Z | - |
dc.date.available | 2021-10-26T10:37:08Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Terpos, E. (Evangelos); Kostopoulos, I.V. (Ioannis V.); Kastritis, E. (Efstathios); et al. "Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapy". HemaSphere. 3 (6), 2019, e300 | es |
dc.identifier.issn | 2572-9241 | - |
dc.identifier.uri | https://hdl.handle.net/10171/62276 | - |
dc.description.abstract | Minimal residual disease (MRD) was monitored in 52 patients with sustained CR (≥2 years) after frontline therapy using next-generation flow (NGF) cytometry. 25% of patients initially MRD- reversed to MRD+. 56% of patients in sustained CR were MRD+; 45% at the level of 10−5; 17% at 10−6. All patients who relapsed during follow-up were MRD+ at the latest MRD assessment, including those with ultra-low tumor burden. MRD persistence was associated with specific phenotypic profiles: higher erythroblasts’ and tumor-associated monocytes/macrophages’ predominance in the bone marrow niche. NGF emerges as a suitable method for periodic, reproducible, highly-sensitive MRD-detection at the level of 10−6. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Ovid Technologies (Wolters Kluwer Health) | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Minimal residual disease (MRD) | es_ES |
dc.subject | Phenotypic profiles | es_ES |
dc.subject | Suitable method | es_ES |
dc.subject | Next-generation flow (NGF) | es_ES |
dc.title | Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapy | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.note | This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) | es_ES |
dc.identifier.doi | 10.1097/HS9.0000000000000300 | - |
dadun.citation.number | 6 | es_ES |
dadun.citation.publicationName | HemaSphere | es_ES |
dadun.citation.startingPage | e300 | es_ES |
dadun.citation.volume | 3 | es_ES |
Ficheros en este ítem:
Estadísticas e impacto
Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.